Research Topics
Species | Lisa C Costello-BoerrigterSummaryAffiliation: Mayo Clinic Country: USA Publications
| Collaborators
|
Detail Information
Publications
The effect of the brain-type natriuretic peptide single-nucleotide polymorphism rs198389 on test characteristics of common assaysLisa C Costello-Boerrigter
Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA
Mayo Clin Proc 86:210-8. 2011....
Mineralocorticoid escape by the kidney but not the heart in experimental asymptomatic left ventricular dysfunctionLisa C Costello-Boerrigter
Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic and Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
Hypertension 50:481-8. 2007..Despite renal escape, increased left ventricular collagen deposition suggests that the heart but not the kidney failed to escape the tissue effects of DOCA...- The prognostic value of N-terminal proB-type natriuretic peptideLisa C Costello-Boerrigter
Mayo Clinic and Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Nat Clin Pract Cardiovasc Med 2:194-201. 2005..This review summarizes current literature that has addressed the issue of NT-proBNP as a prognostic tool in heart failure, acute coronary syndromes and other conditions... - Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failureLisa C Costello-Boerrigter
Cardiorenal Research Laboratory, Guggenheim 915, Mayo Clinic and College of Medicine, 200 First St SW, Rochester, MN 55905, USA
Am J Physiol Renal Physiol 290:F273-8. 2006..We conclude that tolvaptan is an effective aquaretic with no adverse effects on renal hemodynamics or serum electrolytes in patients with mild to moderate heart failure... - V2 receptor antagonism with tolvaptan in heart failureLisa C Costello-Boerrigter
Cardiorenal Research Laboratory, Mayo Clinic and Mayo Clinic College of Medicine, Guggenheim 9, 200 First Street SW, Rochester, MN 55905, USA
Expert Opin Investig Drugs 16:1639-47. 2007..In this paper, the authors review the pharmacology of tolvaptan and discuss the results of the initial clinical trials with this potent new drug... 
Pharmacology of vasopressin antagonistsLisa C Costello-Boerrigter
Cardiorenal Research Laboratory, Mayo Clinic and Mayo Clinic College of Medicine, Guggenheim 9, 200 First Street SW, Rochester, MN 55905, USA
Heart Fail Rev 14:75-82. 2009..e. they excrete free water. We review the pharmacology of non-selective V(1A)/V(2) receptor antagonists and selective V(2) receptor antagonists currently in clinical development...- Renal and anti-aldosterone actions of vasopressin-2 receptor antagonism and B-type natriuretic peptide in experimental heart failureLisa C Costello-Boerrigter
Cardiorenal Research Laboratory, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
Circ Heart Fail 3:412-9. 2010.... - Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunctionLisa C Costello-Boerrigter
Cardiorenal Research Laboratory, Mayo Clinic and Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
J Am Coll Cardiol 47:345-53. 2006..This study sought to characterize factors influencing amino-terminal pro-B-type natriuretic peptide (NT-proBNP) and to evaluate the ability of NT-proBNP to detect left ventricular (LV) dysfunction in a large community sample... - Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failureGuido Boerrigter
Cardiorenal Research Laboratory, Mayo Clinic and Foundation, Rochester, MN 55905, USA
Circulation 107:686-9. 2003..To date, its therapeutic actions in congestive heart failure (CHF) remain undefined. We characterized the cardiorenal actions of intravenous BAY 41-2272 in a canine model of CHF and compared it to nitroglycerin (NTG)... - Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failureAlessandro Cataliotti
Cardiorenal Research Laboratory, Department of Physiology and Internal Medicine, Mayo Clinic and Foundation, Rochester, Minn 55905, USA
Circulation 109:1680-5. 2004..The objective of this study was to test the hypothesis that exogenous BNP enhances the renal diuretic and natriuretic actions of furosemide (Fs) and retards the activation of aldosterone in a model of CHF... - Brain natriuretic Peptide is produced in cardiac fibroblasts and induces matrix metalloproteinasesToshihiro Tsuruda
Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, Minn 55905, USA
Circ Res 91:1127-34. 2002..These in vitro findings support a role for BNP as a regulator of myocardial structure via control of cardiac fibroblast function... - B-type natriuretic peptide 8-32, which is produced from mature BNP 1-32 by the metalloprotease meprin A, has reduced bioactivityGuido Boerrigter
Cardiorenal Research Laboratory, Guggenheim 915, Mayo Clinic and Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
Am J Physiol Regul Integr Comp Physiol 296:R1744-50. 2009..Meprin A inhibition may be a potential strategy to increase the bioactivity of endogenous and exogenous BNP 1-32 in cardiovascular diseases... - Des-serine-proline brain natriuretic peptide 3-32 in cardiorenal regulationGuido Boerrigter
Cardiorenal Research Laboratory, Guggenheim 915, Mayo Clinic and Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
Am J Physiol Regul Integr Comp Physiol 292:R897-901. 2007..4* ml/min with BNP 1-32. Plasma BNP immunoreactivity was lower with BNP 3-32, suggesting accelerated degradation. In this study, BNP 3-32 showed reduced natriuresis and diuresis and a lack of vasodilating actions compared with BNP 1-32... - Oral human brain natriuretic peptide activates cyclic guanosine 3',5'-monophosphate and decreases mean arterial pressureAlessandro Cataliotti
Department of Physiology and Internal Medicine, Mayo Clinic and Foundation, Rochester, MN 55905, USA
Circulation 112:836-40. 2005..We hypothesized that novel oral conjugated hBNP (CONJ-hBNP) increases plasma hBNP, activates cGMP, and reduces mean arterial pressure (MAP)... - Targeting heme-oxidized soluble guanylate cyclase in experimental heart failureGuido Boerrigter
Cardiorenal Research Laboratory, Mayo Clinic and Foundation, Rochester, MN 55905, USA
Hypertension 49:1128-33. 2007..These beneficial properties make direct soluble guanylate cyclase stimulation with BAY 58-2667 a promising new therapeutic strategy for cardiovascular diseases, such as heart failure... - Revisiting salt and water retention: new diuretics, aquaretics, and natriureticsLisa C Costello-Boerrigter
Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
Med Clin North Am 87:475-91. 2003..Many questions remain unanswered, and studies are needed to demonstrate that the positive results seen in basic research translate into improved morbidity and mortality... - A genetic variant of the atrial natriuretic peptide gene is associated with cardiometabolic protection in the general communityValentina Cannone
Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic and Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
J Am Coll Cardiol 58:629-36. 2011..We sought to define the cardiometabolic phenotype associated with rs5068, a genetic variant of the atrial natriuretic peptide (ANP) gene... - Cardiac resynchronization therapy improves renal function in human heart failure with reduced glomerular filtration rateGuido Boerrigter
Cardiorenal Research Laboratory, Mayo Clinic and Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
J Card Fail 14:539-46. 2008..We hypothesized that CRT would improve glomerular filtration rate as estimated by the abbreviated Modification of Diet in Renal Disease equation (eGFR)... - Impaired natriuretic and renal endocrine response to acute volume expansion in pre-clinical systolic and diastolic dysfunctionPaul M McKie
Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
J Am Coll Cardiol 58:2095-103. 2011..We further hypothesized that exogenous B-type natriuretic peptide (BNP) could rescue an impaired natriuretic response in PSD and PDD... - Ventricular adrenomedullin is associated with myocyte hypertrophy in human transplanted heartToshihiro Tsuruda
Cardiorenal Research Laboratory, Mayo Clinic and Foundation, 200 First Street, SW, Rochester, MN 55905, USA
Regul Pept 112:161-6. 2003.... - Chronic actions of a novel oral B-type natriuretic peptide conjugate in normal dogs and acute actions in angiotensin II-mediated hypertensionAlessandro Cataliotti
Cardiorenal Research Laboratory, Mayo Clinic and Foundation, Rochester, MN 55905, USA
Circulation 118:1729-36. 2008..We also sought to establish the ability of this new conjugate to acutely activate cGMP and to reduce blood pressure in an experimental model of angiotensin II (ANG II) -mediated hypertension... - Natriuretic peptides in the diagnosis and management of chronic heart failureGuido Boerrigter
Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Heart Fail Clin 5:501-14. 2009..Likewise, accounting for rs198389 (a common single nucleotide polymorphism that increases BNP levels) may help to further refine the use of components of the BNP system as biomarkers... - Human hypertension is characterized by a lack of activation of the antihypertensive cardiac hormones ANP and BNPFima Macheret
Department of Medicine, Weill Cornell Medical College, New York Presbyterian Hospital, New York, New York 10065, USA
J Am Coll Cardiol 60:1558-65. 2012.... - Matrix metalloproteinases: pathways of induction by bioactive moleculesToshihiro Tsuruda
Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Heart Fail Rev 9:53-61. 2004.... - Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeuticsSarah Mangiafico
Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic and Mayo Clinic College of Medicine, Guggenheim 9, 200 First Street SW, Rochester, MN 55901, USA
Eur Heart J 34:886-893c. 2013..This review summarizes the current knowledge of the use and effects of NEPinh alone or in combination with other therapeutic agents for the treatment of human cardiovascular disease such as HF and hypertension... - Elevated plasma human urotensin-II-like immunoreactivity in ischemic cardiomyopathyHarald Lapp
Herzzentrum Wuppertal, HELIOS Klinikum, Wuppertal, Germany
Int J Cardiol 94:93-7. 2004..Little is known about the pathophysiological relevance of hU-II. We hypothesised that circulating hU-II is elevated in patients with coronary artery disease (CAD) corresponding to the degree of cardiac dysfunction...